BUTACLAMOL

Details

Stereochemistry	RACEMIC
Molecular Formula	C25H31NO
Molecular Weight	361.5197
Optical Activity	( + / - )
Defined Stereocenters	3 / 3
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@]12C[C@](O)(CCN1C[C@]3([H])C4=CC=CC=C4CCC5=CC=CC2=C35)C(C)(C)C

InChI

InChIKey=ZZJYIKPMDIWRSN-TZBSWOFLSA-N

InChI=1S/C25H31NO/c1-24(2,3)25(27)13-14-26-16-21-19-9-5-4-7-17(19)11-12-18-8-6-10-20(23(18)21)22(26)15-25/h4-10,21-22,27H,11-16H2,1-3H3/t21-,22-,25-/m1/s1

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/355181

Butaclamol is an antipsychotic drug, which was studied for the treatment of schizophrenia. This drug has never marketed and now is used in research, because of its action as a dopamine receptor-blocking agent. Butaclamol consists of the two forms: (-)-butaclamol, an inactive drug and (+)-butaclamol, a potent neuroleptic drug.

CNS Activity

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Dopamine receptor 60 Target ID: CHEMBL2096905 Sources: https://www.ncbi.nlm.nih.gov/pubmed/908278	Blocker 537

Conditions

Condition	Modality	Targets	Highest Phase	Product
Schizophrenia 298 Sources: https://www.ncbi.nlm.nih.gov/pubmed/355181	Primary		Not Provided 504	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
[3H]-DOB(4-bromo-2,5-dimethoxyphenylisopropylamine) and [3H] ketanserin label two affinity states of the cloned human 5-hydroxytryptamine2 receptor.	1990 Nov	2233697
Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1.	1991 Apr 18	1826762
Neurochemical and functional characterization of the preferentially selective dopamine D3 agonist PD 128907.	1995 Dec	8531103
Lack of discrimination by agonists for D2 and D3 dopamine receptors.	1995 Jul	7576010
Identification and pharmacological characterization of [125I]L-750,667, a novel radioligand for the dopamine D4 receptor.	1996 Dec	8967990

Patents

Sample Use Guides

In Vivo Use Guide

Maximum clinical response appeared to be at the 20-40 mg. dose level. Extrapyramidal signs occurred at all doses, but with greater severity at higher doses. Excessive daytime drowsiness occurred in all groups but with longer duration and greater intensity in the 20 mg. group.

Route of Administration: Intraperitoneal

In Vitro Use Guide

Unknown

Name

Type

Language

BUTACLAMOL

Official Name

English

butaclamol [INN]

Common Name

English

1H-BENZO(6,7)CYCLOHEPTA(1,2,3-DE)-PYRIDO(2,1-A)ISOQUINOLIN-3-OL, 3-(1,1-DIMETHYLETHYL)-2,3,4,4A,8,9,13B,14-OCTAHYDRO-, (3.ALPHA.,4A.ALPHA.,13B.BETA.)-(±)-

Common Name

English

(±)-3.ALPHA.-TERT-BUTYL-2,3,4,4A.BETA.,8,9,13B.ALPHA.,14-OCTAHYDRO-1H-BENZO(6,7)-CYCLOHEPTA(1,2,3-DE)PYRIDO(2,1-A)ISOQUINOLIN-3-OL

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C66883